X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (78194) 78194
Newsletter (46207) 46207
Book Review (7690) 7690
Publication (4085) 4085
Conference Proceeding (2974) 2974
Newspaper Article (2715) 2715
Transcript (398) 398
Book Chapter (177) 177
Dissertation (154) 154
Magazine Article (141) 141
Trade Publication Article (43) 43
Book / eBook (20) 20
Web Resource (11) 11
Reference (10) 10
Data Set (3) 3
Government Document (2) 2
Paper (2) 2
Journal / eJournal (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lung cancer, non-small cell (79658) 79658
cancer (51574) 51574
humans (48459) 48459
index medicus (48047) 48047
research (45218) 45218
oncology (31977) 31977
care and treatment (31174) 31174
oncology, experimental (28794) 28794
female (26805) 26805
male (26766) 26766
lung neoplasms - pathology (23027) 23027
middle aged (22944) 22944
aged (22144) 22144
carcinoma, non-small-cell lung - pathology (20998) 20998
lung cancer (20920) 20920
lung cancer, small cell (19040) 19040
chemotherapy (18754) 18754
carcinoma, non-small-cell lung - drug therapy (17628) 17628
lung neoplasms - drug therapy (17240) 17240
non-small cell lung cancer (17029) 17029
reports (15809) 15809
prognosis (15613) 15613
adult (13949) 13949
genetic aspects (12170) 12170
analysis (11771) 11771
respiratory system (11674) 11674
carcinoma, non-small-cell lung - genetics (11203) 11203
lung neoplasms - genetics (11089) 11089
metastasis (10920) 10920
neoplasm staging (10699) 10699
aged, 80 and over (9178) 9178
lung neoplasms - mortality (8973) 8973
tumors (8886) 8886
carcinoma, non-small-cell lung - mortality (8822) 8822
radiotherapy (8554) 8554
universities and colleges (8399) 8399
survival (7849) 7849
health aspects (7765) 7765
treatment outcome (7735) 7735
lung neoplasms - metabolism (7632) 7632
carcinoma, non-small-cell lung - metabolism (7502) 7502
surgery (7422) 7422
carcinoma (7168) 7168
antineoplastic agents (6909) 6909
lung neoplasms - surgery (6896) 6896
medical research (6837) 6837
apoptosis (6831) 6831
carcinoma, non-small-cell lung - surgery (6825) 6825
antimitotic agents (6743) 6743
drug therapy (6717) 6717
antineoplastic combined chemotherapy protocols - therapeutic use (6523) 6523
physical fitness (6262) 6262
cell line, tumor (6155) 6155
mutation (6018) 6018
development and progression (6007) 6007
retrospective studies (5880) 5880
medicine, experimental (5839) 5839
clinical trials (5830) 5830
expression (5784) 5784
epidermal growth factor (5655) 5655
survival rate (5397) 5397
biochemistry (5393) 5393
hematology, oncology and palliative medicine (5185) 5185
gefitinib (5159) 5159
antineoplastic agents - therapeutic use (5028) 5028
animals (5022) 5022
adenocarcinoma (5013) 5013
communicable diseases (4800) 4800
survival analysis (4734) 4734
non-small-cell lung cancer (4721) 4721
nsclc (4712) 4712
carcinoma, non-small-cell lung - radiotherapy (4695) 4695
pharmaceutical industry (4645) 4645
lung neoplasms - radiotherapy (4564) 4564
lung neoplasms - therapy (4561) 4561
diagnosis (4558) 4558
carcinoma, non-small-cell lung - therapy (4552) 4552
patient outcomes (4436) 4436
drugs (4325) 4325
cisplatin (4302) 4302
cell research (4261) 4261
immunotherapy (4231) 4231
immunohistochemistry (4175) 4175
abridged index medicus (4107) 4107
non-small cell lung carcinoma (4103) 4103
cancer therapies (3987) 3987
gene expression (3971) 3971
therapy (3907) 3907
radiology, nuclear medicine & medical imaging (3836) 3836
lung neoplasms - diagnosis (3762) 3762
carcinoma, non-small-cell lung - diagnosis (3712) 3712
risk factors (3696) 3696
patients (3688) 3688
erlotinib (3680) 3680
cell lung-cancer (3558) 3558
mice (3462) 3462
respiratory tract diseases (3420) 3420
disease-free survival (3382) 3382
radiation (3340) 3340
follow-up studies (3248) 3248
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (124184) 124184
Chinese (1564) 1564
French (1246) 1246
Japanese (927) 927
German (570) 570
Korean (265) 265
Spanish (237) 237
Polish (228) 228
Russian (161) 161
Turkish (112) 112
Italian (92) 92
Portuguese (59) 59
Czech (54) 54
Hungarian (45) 45
Dutch (20) 20
Bulgarian (16) 16
Romanian (13) 13
Danish (12) 12
Serbian (11) 11
Icelandic (9) 9
Slovak (9) 9
Finnish (8) 8
Lithuanian (8) 8
Croatian (6) 6
Norwegian (6) 6
Hebrew (5) 5
Swedish (5) 5
Belarusian (1) 1
Bosnian (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2001, Basic and clinical oncology, ISBN 0824702743, Volume 25., 535
Book
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
2005, Hematology/oncology clinics of North America, ISBN 9781416027737, Volume 19, no. 2., xii, p. 209-426
Book
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e60317 - e60317
Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in the development and progression of various types of cancers. However, its... 
SUPPRESSOR | ONCOGENESIS | RNA | MULTIDISCIPLINARY SCIENCES | CERVICAL-CANCER | INTERFERENCE | MICRORNAS | NF-KAPPA-B | FACTOR RECEPTOR | EXPRESSION | CONTRIBUTES | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | MicroRNAs - metabolism | NF-kappa B - metabolism | Receptor, Epidermal Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Lung - metabolism | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung - drug effects | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | MicroRNAs - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Apoptosis | Cell Movement | MicroRNA | Growth | Monoclonal antibodies | Lung cancer, Small cell | Development and progression | Lung cancer, Non-small cell | Health aspects | Cell proliferation | Laboratories | Lung | Lung cancer | Oncology | Drug delivery | Kinases | Paraffin | Cancer therapies | Metastases | Signal transduction | Cell growth | Bioindicators | Inhibition | Gefitinib | Sensitizing | NF-κB protein | Phenotypes | Cytokines | Epidermal growth factor receptors | MiRNA | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Ribonucleic acid--RNA | Patients | Pathology | Signaling | Chemotherapy | Thyroid cancer | MicroRNAs | Medical prognosis | Pancreatic cancer | Cell lines | Biomarkers | Mutation | Cell migration | Cervical cancer | Tumors | Cancer | Index Medicus | Ribonucleic acid
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung | Lung cancer | Diarrhea | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 08/2014, Volume 111, Issue 34, pp. E3553 - E3561
MicroRNAs (miRNAs) and siRNAs have enormous potential as cancer therapeutics, but their effective delivery to most solid tumors has been difficult. Here, we... 
miR-34 | Nanotechnology | MULTIDISCIPLINARY SCIENCES | MICRORNAS | MUTANT KRAS | DELIVERY | K-RAS | MOUSE MODEL | nanotechnology | TUMOR-SUPPRESSION | INTERFERENCE | SIRNA | P53 NETWORK | PROGRESSION | MicroRNAs - therapeutic use | RNA, Small Interfering - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Lung Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | RNA, Neoplasm - metabolism | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | MAP Kinase Signaling System | Adenocarcinoma - metabolism | Nanoparticles - therapeutic use | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Gene Expression | Carcinoma, Non-Small-Cell Lung - genetics | MicroRNAs - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Mice, Transgenic | Proto-Oncogene Proteins - genetics | Combined Modality Therapy | Lung Neoplasms - therapy | Tumor Suppressor Protein p53 - deficiency | Mice, Knockout | Carcinoma, Non-Small-Cell Lung - therapy | Animals | Adenocarcinoma - therapy | RNA, Small Interfering - therapeutic use | Cell Line, Tumor | RNA, Neoplasm - genetics | Mice | MicroRNAs - genetics | Nanoparticles - administration & dosage | Mutation | RNA, Small Interfering - administration & dosage | Cancer therapies | MicroRNAs | Lung cancer | Tumors | Index Medicus | Biological Sciences | PNAS Plus
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2012, Volume 7, Issue 4, pp. e35065 - e35065
Background: Lysine specific demethylase 1 (LSD1) has been identified and biochemically characterized in epigenetics, but the pathological roles of its... 
BREAST-CANCER | HISTONE DEMETHYLASES | PROGRAMS | BIOLOGY | Immunohistochemistry | RNA, Small Interfering - genetics | Histone Demethylases - antagonists & inhibitors | Prognosis | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Epithelial-Mesenchymal Transition - genetics | Histone Demethylases - genetics | Cell Movement - genetics | Adult | Female | Lung - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Carcinoma, Non-Small-Cell Lung - genetics | Neoplasm Invasiveness | Carcinoma, Non-Small-Cell Lung - metabolism | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Cell Movement - drug effects | Lung - drug effects | Cell Line, Tumor | Pargyline - pharmacology | Aged | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Epigenetic inheritance | RNA | Analysis | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | T cells | Health aspects | Cancer | Cell proliferation | Mesenchyme | Lung | Lung cancer | Biology | mRNA | Statistical methods | Metastasis | Neuroblastoma | Assaying | Cancer therapies | Nuclei | Phase transitions | Western blotting | Cell cycle | DNA methylation | Medical research | Enzymes | Statistical analysis | Cell survival | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Biological assays | Patients | Medicine | Studies | Androgens | Overexpression | Lysine | Epigenetics | Nuclei (cytology) | Immunofluorescence | Pargyline | Prostate cancer | Cell migration | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article